Contineum Therapeutics, Inc. (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology ...

Xenon Pharmaceuticals Inc. , a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that ...

NASA's Artemis campaign is rapidly advancing the development of Gateway, a space station that will orbit the Moon and serve ...

Xenon Pharmaceuticals reported an EPS of -0.84, slightly better than the forecast of -0.85. The company's stock dropped by 2.02% during regular trading and fell further in aftermarket trading ...

NASA’s ambitious Artemis program is making steady progress toward its goal of establishing a long-term human presence on the Moon—and at the center of this effort is Gateway, a lunar space station ...

As an antagonist of the NMDA subtype of the glutamate receptor, [3] xenon has been extensively investigated for its molecular action in neuroprotection against acute neuronal injury. In this ...

These findings set the stage for the current studies, which provide the first molecular pictures of KBTBD4 targeting the CoREST complex through interactions induced by both cancer mutations and a ...

Currently, there is a distinct lack of effective clinical strategies to obviate this problem. Xenon, a noble gas with anesthetic properties, exhibits neuroprotective effects. It is reliable ...

Univ. Bordeaux, CNRS, Bordeaux INP, CBMN, UMR 5248, IECB, F-33607 Pessac, France ...

Two new studies represent a big step toward developing innovative molecular therapies capable of disrupting the uncontrollable growth of cancers at their roots. These studies provide insights into ...